Psychiatr. pro Praxi, 2003; 5: 227-229

®ádoucí změna preskripce z flunitrazepamu na Zolpidem a Zopiklon

prof. MUDr. Jaromír ©vestka DrSc
Psychiatrická klinika LF MU a FN Brno

Published: December 31, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©vestka J. ®ádoucí změna preskripce z flunitrazepamu na Zolpidem a Zopiklon. Psychiatr. praxi. 2003;4(5):227-229.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bocca ML, Le Doze F, Etard O, et al. Residual effect of zolpidem 10 mg and zopiclone 7,5 mg versus flunitrazepam 1 mg and placebo on driving performance and occular saccades. Psychopharmacology 1999; 143: 373-379. Go to original source... Go to PubMed...
    2. Borman J. The, ,ABC" of GABA receptors. Trends Pharmacol Sci 2000; 21: 16-19. Go to original source... Go to PubMed...
    3. Cluydts R, Peeters K, de Bouyalsky I, Lavoise J. Comparison of continuous versus intermittent administration of zolpidem in chronic insomniacs: A double-blind randomized pilot study. J Int Med Res 1998; 26: 13-24. Go to original source... Go to PubMed...
    4. Daderman AM, Fredricksson B, Kristiansson M et al. Violent behaviour, impulsive decision-making, and anterograde amnesia while intoxicated with flunitrazepam and alcohol and other drugs. J Am Acad Psychiat Law 2002; 30: 238-251.
    5. Denise P, Bocca ML. Effects of zolpidem 10 mg, zopiclone 7,5 mg and flunitrazepam 1 mg on night-time motor activity. Eur Neuropsychopharmacol 2003; 13: 111-115. Go to original source... Go to PubMed...
    6. Dikeos DG, Soldatos CR. The pharmacotherapy of insomnia: Efficacy and rebound with hypnotic drugs. Prim Care Comp J Clin Psychiat 2002; 4 (Suppl. 1): 27-32.
    7. Druid H, Holmgren P, Ahlner J. Flunitrazepam: An evaluation of use, abuse and toxicity. Forens Sci Int 2001; 122: 136-141. Go to original source... Go to PubMed...
    8. Dujardin K, Guieu JD, Leconte-Lambert C, et al. Comparison of the effect of zolpidem and flunitrazepam on sleep structure and daytime cognitive functions. A study of untreated insomniacs. Pharmacopsychiatry 1998; 31: 14-18. Go to original source... Go to PubMed...
    9. Hajak G, Cluydts R, Declerck A, Estivill SE, Middleton A, ©onka A, Undén M. Continuous versus non-nightly use of zolpidem in chronic insomnia: Results of a large-scale, double-blind, randomized outpatient study. Int Clin Psychopharmacol 2002; 17: 9-17. Go to original source... Go to PubMed...
    10. Hajak G. A comparative assessment of the risks and benefits of zopiclone: A review of 15 years´clinical experience. Drug Safety 1999; 21: 457-469. Go to original source... Go to PubMed...
    11. Hajak G, Clarenbach P, Fischer W, et al. Rebound insomnia after hypnotic withdrawal in insomniac outpatients. Eur Arch Psychiat Clin Neurosci 1998; 248: 148-156. Go to original source... Go to PubMed...
    12. Hanlon JT, Horner RD, Schmader KE, et al. Benzodiazepine use and cognitive function among community. dwelling elderly. Clin Pharmacol 1998; 64: 684-692. Go to original source... Go to PubMed...
    13. Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 1997; 278: 27-31. Go to original source...
    14. Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of insomnia. Can Med Ass J 2000; 62: 225-233.
    15. Holm KJ, Goa KL. Zolpidem: An update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 2000; 59: 865-889. Go to original source... Go to PubMed...
    16. Lader M. Withdrawal reactions after stopping hypnotics in patients with insomnia. CNS Drugs 1998; 10: 425-440. Go to original source...
    17. Noble S, Langtry HD, Lamb HM. Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1998; 55: 277-302. Go to original source... Go to PubMed...
    18. Nowell PD, Mazundar S, Buysse DJ, et al. Benzodiazepines and zolpidem for chronic insomnia: A meta-analysis of treatment efficacy. JAMA 1997; 278: 2170-2177. Go to original source... Go to PubMed...
    19. Smith KM, Lerive LL, Romanelli F. Club drugs: methylene dioxymetamphetamine, flunitrazepam, ketamine, and gamma-hydroxybutyrate. Am J Health Syst Pharmacy 2002; 59: 1067-1076. Go to original source... Go to PubMed...
    20. Soldatos CR, Dikeos DG, Whitehead A. Tolerance and rebound insomnia with rapidly eliminated hypnotics: A meta-analysis of sleep laboratory studies. Int Clin Psychopharmacol 1999; 14: 287-303. Go to original source... Go to PubMed...
    21. Terzano MG, Rossi M, Palomba V, et al. New drugs for insomnia. Comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Safety 2003; 26: 261-282. Go to original source... Go to PubMed...
    22. Thomas RE. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. Can Fam Physician 1998; 44: 799-808. Go to PubMed...
    23. Wang PS, Bohn RL, Glynn RJ, et al. Hazardous benzodiazepine regimens in the elderly. Effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry 2001; 158: 892-898. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.